Researchers have found in DELTA China trial that delgocitinib cream (Anzupgo) 20 mg/g significantly reduces severity of ...

Leo Pharma forecasts first profit since 2018, following restructuring. CEO Bourdon reports strong 2024 sales of 10B DKK, EU ...

Danish dermatology specialist LEO Pharma has announced results showing a strong performance in 2024, with both sales growth ...

"2024 was a year of strong progress for LEO Pharma with double-digit growth in sales and another year of significantly ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development. The pharmaceutical company’s Boston-based R&D ...

Under the agreement, LEO Pharma will be responsible for toripalimab’s distribution, promotion, sales, etc., in up to 32 countries, including all member states of the European Union (EU ...

LEO Pharma delivered another year of strong progress in 2024, with both sales growth and adjusted EBITDA margin ahead of the initial outlook for the year, putting the company on track to meet its ...

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma delivered another year of strong progress in 2024, with both sales growth and adjusted EBITDA margin ahead of the initial outlook for the year ...